Characterization of an antibody that can detect an activated IGF-I receptor in human cancers

Experimental Cell Research

Volumn 251, Issue 1, 1999, Pages 22-32

  Rubini, Michele ^a   D'Ambrosio, Consuelo ^b   Carturan, Sabrina ^a   Yumet, Gladys ^c   Catalano, Edison ^d   Shan, Simei ^c   Huang, Ziwei ^c   Criscuolo, Mario ^b   Pifferi, Micol ^b   Baserga, Renato ^c  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d Department of Anesthesiology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; LIGAND; SOMATOMEDIN C; TYROSINE;

ANIMAL CELL; ANTIBODY SPECIFICITY; APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; AUTOPHOSPHORYLATION; CANCER; CARBOXY TERMINAL SEQUENCE; MALIGNANT TRANSFORMATION; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; PARACRINE SIGNALING; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROGNOSIS; SIGNAL TRANSDUCTION;

EID: 0033603824     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1006/excr.1999.4562     Document Type: Article

References (62)

1. Baserga R., Hongo A., Rubini M., Prisco M., Valentinis B. The IGF-I receptor in cell growth, transformation and apoptosis. Biochim. Biophys. Acta. 1332:1997;105-126.
2. Kaleko M., Rutter W. G., Miller A. D. Overexpression of the human insulin-like growth factor 1 receptor promotes ligand-dependent neoplastic transformation. Mol. Cell. Biol. 10:1990;464-473.
3. Pietrzkowski Z., Lammers R., Carpenter G., Soderquist A. M., Limardo M., Phillips P. D., Ullrich A., Baserga R. Constitutive expression of insulin-like growth factor 1 and insulin-like growth factor 1 receptor abrogates all requirements for exogenous growth factors. Cell Growth Differ. 3:1992;199-205.
4. Resnicoff M., Coppola D., Sell C., Rubin R., Ferrone S., Baserga R. Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type 1 insulin-like growth factor receptor. Cancer Res. 54:1994;4848-4850.
5. Resnicoff M., Sell C., Rubini M., Coppola D., Ambrose D., Baserga R., Rubin R. Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor I (IGF-I) receptor are non-tumorigenic and induce regression of wild-type tumors. Cancer Res. 54:1994;2218-2222.
6. Shapiro D. N., Jones B. G., Shapiro L. H., Dias P., Houghton P. J. Antisense-mediated reduction in insulin-like growth factor 1 receptor expression suppresses the malignant phenotype of a human alveolar rhabdomyosarcoma. J. Clin. Invest. 94:1994;1235-1242.
7. Lee C. T., Wu S., Gabrivolich D., Chen H., Nadaf-Rahrov S., Ciernick I. F., Carbone D. P. Antitumor effect of an adenovirus expressing antisense insulin-like growth factor I receptor on human lung cancer cell lines. Cancer Res. 56:1996;3038-3041.
8. Pass H. L., Mew D. J. Y., Carbone M., Matthews W. A., Domington J. S., Baserga R., Walker C. L., Resnicoff M., Steinberg S. M. Inhibition of hamster mesothelioma tumorigenesis by an antisense expression plasmid to the insulin-like growth factor I receptor. Cancer Res. 56:1996;4044-4048.
9. Rininsland F., Johnson T. R., Chernicky C. L., Schulze E., Burfeind B., Ilan J., Ilan J. Suppression of insulin-like growth factor I receptor by a triple-helix strategy inhibits IGF-I transcription and tumorigenic potential of rat C6 glioblastoma cells. Proc. Natl. Acad. Sci. USA. 94:1997;5854-5859.
10. D'Ambrosio C., Ferber A., Resnicoff M., Baserga R. A soluble insulin-like growth factor I receptor that induces apoptosis of tumor cells in vivo and inhibits tumorigenesis. Cancer Res. 56:1996;4013-4020.
11. Prager D., Li H. L., Asa S., Melmed S. Dominant negative inhibition of tumorigenesis in vivo by human insulin-like growth factor receptor mutant. Proc. Natl. Acad. Sci. USA. 91:1994;2181-2185.
12. Long L., Rubin R., Baserga R., Brodt P. Loss of the metastatic phenotype in murine carcinoma cells expressing an antisense RNA to the insulin-like growth factor I receptor. Cancer Res. 55:1995;1006-1009.
13. Burfeind P., Chernicky C. L., Rininsland F., Ilan J., Ilan J. Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo. Proc. Natl. Acad. Sci. USA. 93:1996;7263-7268.
14. Dunn S. E., Ehrlich M., Sharp N. J. H., Reiss K., Solomon G., Hawkins R., Baserga R., Barrett J. C. A dominant negative mutant of the insulin-like growth factor-1 receptor inhibits the adhesion, invasion and metastasis of breast cancer. Cancer Res. 58:1998;3353-3361.
15. McCubrey J. A., Stillman L. S., Mayhew M. W., Algate P. A., Dellow R. A., Kaleko M. Growth promoting effects of insulin-like growth factor 1 (IGF-1) on hematopoietic cells. Overexpression of introduced IGF-1 receptor abrogates interleukin-3 dependency of murine factor dependent cells by ligand dependent mechanism. Blood. 78:1991;921-929.
16. Rodriguez-Tarduchy G., Collins M. K. L., Garcia I., Lopez-Rivas A. Insulin-like growth factor I inhibits apoptosis in IL-3 dependent hemopoietic cells. J. Immunol. 149:1992;535-540.
17. O'Connor R., Kauffmann-Zeh A., Liu Y., Lehar S., Evan G. I., Baserga R., Blattler W. A. The IGF-I receptor domains for protection from apoptosis are distinct from those required for proliferation and transformation. Mol. Cell. Biol. 17:1997;427-435.
18. Zhou-Li F., Xu S., Dews M., Baserga R. Co-operation of simian virus 40 T antigen and insulin receptor substrate-1 in protection from apoptosis induced by Interleukin-3 withdrawal. Oncogene. 15:1997;961-970.
19. Dews M., Nishimoto I., Baserga R. IGF-I receptor protection from apoptosis in cells lacking the IRS proteins. Receptors Signal Transduct. 7:1997;231-239.
20. Harrington E. A., Bennett M. R., Fanidi A., Evan G. I. c-myc-induced apoptosis in fibroblasts is inhibited by specific cytokines. EMBO J. 13:1994;3286-3295.
21. Dunn S. E., Hardman R. A., Kari F. W., Barrett J. C. Insulin-like growth factor 1 (IGF-I) alters drug sensitivity of HBL100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs. Cancer Res. 57:1997;2687-2693.
22. Sell C., Baserga R., Rubin R. Insulin-like growth factor I (IGF-I) and the IGF-I receptor prevent etoposide-induced apoptosis. Cancer Res. 55:1995;303-306.
23. Wu Y., Tewari M., Cui S., Rubin R. Activation of the insulin-like growth factor I receptor inhibits tumor necrosis factor-induced cell death. J. Cell. Physiol. 168:1996;499-509.
24. Hsing A. Y., Kadomatsu K., Bonham N. J., Danielpour D. Regulation of apoptosis induced by transforming growth factor β1 in nontumorigenic and tumorigenic rat prostatic epithelial cell lines. Cancer Res. 56:1996;5146-5149.
25. Prisco M., Hongo A., Rizzo M. G., Sacchi A., Baserga R. The IGF-I receptor as a physiological relevant target of p53 in apoptosis caused by interleukin-3 withdrawal. Mol. Cell. Biol. 17:1997;1084-1092.
26. Kulik G., Klippel A., Weber M. J. Antiapoptotic signaling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol. Cell. Biol. 17:1997;1595-1606.
27. Turner B. C., Haffty B. G., Narayanan L., Yuan J., Havre P. A., Gumbs A. A., Kaplan L., Burgaud J. L., Carter D., Baserga R., Glazer P. M. Insulin-like growth factor 1 receptor overexpression mediates cellular resistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res. 57:1997;3079-3083.
28. Nakamura S., Watanabe H., Miura M., Sasaki T. Effect of the insulin-like growth factor I receptor on ionizing radiation-induced cell death in mouse embryo fibroblasts. Exp. Cell Res. 235:1997;287-294.
29. D'Ambrosio C., Valentinis B., Prisco M., Reiss K., Rubini M., Baserga R. Protective effect of the IGF-I receptor on apoptosis induced by okadaic acid. Cancer Res. 57:1997;3264-3271.
30. Jung Y. K., Miura M., Yuan J. Suppression of interleukin-1 beta converting enzyme-mediated cell death by insulin-like growth factor. J. Biol. Chem. 271:1996;5112-5117.
31. Nystrom F. H., Ohman P. K., Ekman B. A., Osterlund M. K., Karlberg B. E., Arnqvist H. J. Population-based reference values for IGF-I and IGF-binding protein-1: relations with metabolic and anthropometric variables. Eur. J. Endocr. 135:1997;165-172.
32. Bereket A., Wilson T. A., Blethen S. L., Fan J., Frost R. A., Gelato M. C., Lang C. H. Effect of short term fasting on free-dissociable insulin-like growth factor I concentrations in normal human serum. J. Clin. Endocrinol. Metab. 81:1996;4379-4384.
33. Cullen K. J., Yee D., Rosen N. Insulin-like growth factors in human malignancy. Cancer Invest. 9:1991;443-454.
34. Macaulay V. M. Insulin-like growth factors and cancer. Br. J. Cancer. 65:1992;311-320.
35. Peyrat J. P., Bonneterre J., Beuscart R., Djiana J., Demaille A. Insulin-like growth factor I receptors in human breast cancer and their relation to estradiol and progesterone receptors. Cancer Res. 48:1988;6429-6433.
36. Peyrat J. P., Bonneterre J., Hecquet B., Vennin P., Louchez M. M., Fournier C., Lefebvre J., Demaille A. Plasma insulin-like growth factor I (IGF-I) concentrations in human breast cancer. Eur. J. Cancer. 29A:1993;492-497.
37. Railo M. J., Smitten K. V., Pekonen F. The prognostic value of insulin-like growth factor I in breast cancer patients. Results of a follow-up study on 126 patients. Eur. J. Cancer. 30A:1994;307-311.
38. Giani C., Cullen K. J., Campani D., Rasmussen A. IGF-II mRNA and protein are expressed in the stroma of invasive breast cancers: An in situ hybridization and immunohistochemistry study. Breast Cancer Res. Treat. 41:1996;43-50.
39. Chan J. M., Stampfer M. J., Giovannucci E., Gann P. H., Ma J., Wilkinson P., Hennekens C. H., Pollak M. Plasma insulin-like growth factor-1 and prostate cancer risk: A prospective study. Science. 279:1998;563-566.
40. Ullrich A., Gray A., Tam A. W., Yang-Feng T., Tsubokawa M., Collins C., Henzel W., Le Bon T., Kahuria S., Chen E., Jakobs S., Francke U., Ramachandran J., Fujita-Yamaguchi Y. Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J. 5:1986;503-512.
41. Satoh T., Aramini J. M., Li S., Friedman T., Gao J., Edling A., Townsend R., Germann M. W., Korngold R., Huang Z. Bioactive peptide design based on protein surface epitopes: A cyclic heptapeptide mimics CD4 domain 1 CC′ loop and inhibits CD4 biological function. J. Biol. Chem. 272:1997;12175-12180.
42. Li S., Choksi S., Shan S., Hu X., Gao J., Korngold R., Huang Z. Identification of the CD8 DE loop as a surface functional epitope: implications for MHC class I binding and CD8 inhibitor design. J. Biol. Chem. 273:1998;16442-16445.
43. King D. S., Fields C. G., Fields G. B. A cleavage method which minimizes side reactions following Fmoc solid phase peptide synthesis. Int. J. Peptide Protein Res. 36:1990;255-266.
44. Sell C., Dumenil G., Deveaud C., Miura M., Coppola D., DeAngelis T., Rubin R., Efstratiadis A., Baserga R. Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts. Mol. Cell. Biol. 14:1994;3604-3612.
45. Sell C., Rubini M., Rubin R., Liu J. P., Efstratiadis A., Baserga R. Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc. Natl. Acad. Sci. USA. 90:1993;11217-11221.
46. Liu J-P., Baker J., Perkins A. S., Robertson E. J., Efstratiadis A. Mice carrying null mutations of the genes encoding insulin-like growth factor I (igf-1) and type 1 IGF receptor (Igflr). Cell. 75:1993;59-72.
47. Baker J., Liu J-P., Robertson E. J., Efstratiadis A. Role of insulin-like growth factors in embryonic and postnatal growth. Cell. 75:1993;73-82.
48. Surmacz E., Sell C., Swantek J., Kato H., Roberts C. T. Jr., LeRoith D., Baserga R. Dissociation of mitogenesis and transforming activity by C-terminal truncation of the insulin-like growth factor I receptor. Exp. Cell Res. 218:1995;370-380.
49. Miura M., Li S., Baserga R. Effect of a mutation at tyrosine 950 of the insulin-like growth factor I receptor on the growth and transformation of cells. Cancer Res. 55:1995;663-667.
50. Miura M., Surmacz E., Burgaud J. L., Baserga R. Different effects on mitogenesis and transformation of a mutation at tyrosine 1251 of the insulin-like growth factor I receptor. J. Biol. Chem. 270:1995;22639-22644.
51. Li S., Ferber A., Miura M., Baserga R. Mitogenicity and transforming activity of the insulin-like growth factor I receptor with mutations in the tyrosine kinase domain. J. Biol. Chem. 269:1994;32558-32564.
52. Li S., Resnicoff M., Baserga R. Effects of mutations at serines 1280-1283 on the mitogenic and transforming activities of the insulin-like growth factor I receptor. J. Biol. Chem. 271:1996;12254-12260.
53. Hongo A., D'Ambrosio C., Miura M., Morrione A., Baserga R. Mutational analysis of the mitogenic and transforming activities of the insulin-like growth factor I receptor. Oncogene. 12:1996;1231-1238.
54. Coppola D., Ferber A., Miura M., Sell C., D'Ambrosio C., Rubin R., Baserga R. A functional insulin-like growth factor I receptor is required for the mitogenic and transforming activities of the epidermal growth factor receptor. Mol. Cell. Biol. 14:1994;4588-4595.
55. Panneerselvan K., Reitz H., Khan S. A., Bishayee S. A conformational-specific anti-peptide antibody to the β type platelet-derived growth factor receptor also recognizes the activated epidermal growth factor receptor. J. Biol. Chem. 270:1996;7975-7979.
56. Morrione A., Valentinis B., Xu S. Q., Yumet G., Louvi A., Efstratiadis A., Baserga R. Insulin-like growth factor II stimulates cell proliferation through the insulin receptor. Proc. Natl. Acad. Sci. USA. 94:1997;3777-3782.
57. Shier P., Watt V. M. Primary structure of a putative receptor for a ligand of the insulin family. J. Biol. Chem. 264:1989;14605-14608.
58. Colletti R. B., Roberts J. D., Devlin J. T., Copeland K. C. Effect of Tamoxifen on plasma-insulin growth factor 1 in patients with breast cancer. Cancer Res. 49:1989;1882-1884.
59. Pollak M., Costantino J., Polychronakos C., Blauer S., Guyda H., Redmond C., Fisher B., Margolese R. Effect of Tamoxifen on serum insulin-like growth factor 1 levels in stage 1 breast cancer patients. J. Natl. Cancer Inst. 82:1990;1693-1697.
60. Shamah S. M., Alberta J. A., Giannobile W. V., Guha A., Kwon Y. K., Carroll R. S., Black P. M., Stiles C. D. Detection of activated Platelet-derived growth factor receptors in human meningioma. Cancer Res. 57:1997;4141-4147.
61. Epstein R. J., Druker B. J., Roberts T. M., Stiles C. D. Synthetic phosphopeptide immunogens yield activation-specific antibodies to the c-erbB-2 receptor. Proc. Natl. Acad. Sci. USA. 89:1992;10435-10439.
62. Perlman R., Bottaro D. P., White M. F., Kahn C. R. Conformational changes in the α- and β-subunits of the insulin receptor identified by anti-peptide antibodies. J. Biol. Chem. 264:1989;8946-8950.